The EQIPD framework for rigor in the design, conduct, analysis and documentation of animal experiments

EQIPD Consortium

doi:10.1038/s41592-022-01615-y

The EQIPD framework for rigor in the design, conduct, analysis and documentation of animal experiments

EQIPD Consortium

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English
Pages (from-to)	1334–1337
Number of pages	8
Journal	Nature methods
Volume	19
Early online date	5 Sept 2022
DOIs	https://doi.org/10.1038/s41592-022-01615-y
Publication status	Published - 1 Nov 2022

Bibliographical note

Acknowledgements
This work has been conducted as part of the European Quality in Preclinical Data (EQIPD) IMI project, which has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement no. 777364. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation program and EFPIA. We thank Esther Schenker for her contributions to this work. For field testing and surveying the framework, we thank EQIPD work package 4 members as well as Keith Geoffrey Phillips at Eli Lilly and Tony Blockeel at the University of Bristol as part of our collaboration with IMI PainCare (an Innovative Medicines Initiative 2 Joint undertaking under grant agreement no. 777500). This publication reflects only the authors’ view, and the Innovative Medicines Initiative 2 Joint Undertaking is not responsible for any use that may be made of the information it contains.

Keywords

Animal disease models
Publishing
Research management
Mouse
Preclinical research

Access to Document

10.1038/s41592-022-01615-yLicence: Unspecified

Cite this

@article{53f0e16a79224089bc105b6a272c9737,

title = "The EQIPD framework for rigor in the design, conduct, analysis and documentation of animal experiments",

keywords = "Animal disease models, Publishing, Research management, Mouse, Preclinical research",

author = "Jan Vollert and Malcolm Macleod and Ulrich Dirnagl and Kas, {Martien J.} and Michel, {Martin C.} and Heidrun Potschka and Gernot Riedel and Wever, {Kimberley E.} and Hanno W{\"u}rbel and Thomas Steckler and Rice, {Andrew S.C.} and {EQIPD Consortium}",

note = "Acknowledgements This work has been conducted as part of the European Quality in Preclinical Data (EQIPD) IMI project, which has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement no. 777364. This Joint Undertaking receives support from the European Union{\textquoteright}s Horizon 2020 research and innovation program and EFPIA. We thank Esther Schenker for her contributions to this work. For field testing and surveying the framework, we thank EQIPD work package 4 members as well as Keith Geoffrey Phillips at Eli Lilly and Tony Blockeel at the University of Bristol as part of our collaboration with IMI PainCare (an Innovative Medicines Initiative 2 Joint undertaking under grant agreement no. 777500). This publication reflects only the authors{\textquoteright} view, and the Innovative Medicines Initiative 2 Joint Undertaking is not responsible for any use that may be made of the information it contains. ",

year = "2022",

month = nov,

day = "1",

doi = "10.1038/s41592-022-01615-y",

language = "English",

volume = "19",

pages = "1334–1337",

journal = "Nature methods",

issn = "1548-7091",

publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - The EQIPD framework for rigor in the design, conduct, analysis and documentation of animal experiments

AU - Vollert, Jan

AU - Macleod, Malcolm

AU - Dirnagl, Ulrich

AU - Kas, Martien J.

AU - Michel, Martin C.

AU - Potschka, Heidrun

AU - Riedel, Gernot

AU - Wever, Kimberley E.

AU - Würbel, Hanno

AU - Steckler, Thomas

AU - Rice, Andrew S.C.

AU - EQIPD Consortium

N1 - Acknowledgements This work has been conducted as part of the European Quality in Preclinical Data (EQIPD) IMI project, which has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement no. 777364. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation program and EFPIA. We thank Esther Schenker for her contributions to this work. For field testing and surveying the framework, we thank EQIPD work package 4 members as well as Keith Geoffrey Phillips at Eli Lilly and Tony Blockeel at the University of Bristol as part of our collaboration with IMI PainCare (an Innovative Medicines Initiative 2 Joint undertaking under grant agreement no. 777500). This publication reflects only the authors’ view, and the Innovative Medicines Initiative 2 Joint Undertaking is not responsible for any use that may be made of the information it contains.

PY - 2022/11/1

Y1 - 2022/11/1

KW - Animal disease models

KW - Publishing

KW - Research management

KW - Mouse

KW - Preclinical research

UR - http://www.scopus.com/inward/record.url?scp=85137490943&partnerID=8YFLogxK

U2 - 10.1038/s41592-022-01615-y

DO - 10.1038/s41592-022-01615-y

M3 - Comment/debate

C2 - 36064774

AN - SCOPUS:85137490943

SN - 1548-7091

VL - 19

SP - 1334

EP - 1337

JO - Nature methods

JF - Nature methods

ER -

The EQIPD framework for rigor in the design, conduct, analysis and documentation of animal experiments

Bibliographical note

Keywords

Access to Document

Other files and links

Cite this